P G Jacobs1, J El Youssef2, R Reddy3, N Resalat3, D Branigan2, J Condon3, N Preiser3, K Ramsey4, M Jones2, C Edwards2, K Kuehl5, J Leitschuh3, U Rajhbeharrysingh3, J R Castle2. 1. Department of Biomedical Engineering, Oregon Health and Science University, Portland. jacobsp@ohsu.edu. 2. Department of Medicine, Division of Endocrinology, Harold Schnitzer Diabetes Health Center, Oregon Health and Science University, Portland. 3. Department of Biomedical Engineering, Oregon Health and Science University, Portland. 4. Oregon Clinical and Translational Research Institute Biostatistics and Design Program, Oregon Health and Science University, Portland. 5. Department of Medicine, Division of Health Promotion and Sports Medicine, Human Performance Laboratory, Oregon Health and Science University, Portland.
Abstract
AIMS: To test whether adjusting insulin and glucagon in response to exercise within a dual-hormone artificial pancreas (AP) reduces exercise-related hypoglycaemia. MATERIALS AND METHODS: In random order, 21 adults with type 1 diabetes (T1D) underwent three 22-hour experimental sessions: AP with exercise dosing adjustment (APX); AP with no exercise dosing adjustment (APN); and sensor-augmented pump (SAP) therapy. After an overnight stay and 2 hours after breakfast, participants exercised for 45 minutes at 60% of their maximum heart rate, with no snack given before exercise. During APX, insulin was decreased and glucagon was increased at exercise onset, while during SAP therapy, subjects could adjust dosing before exercise. The two primary outcomes were percentage of time spent in hypoglycaemia (<3.9 mmol/L) and percentage of time spent in euglycaemia (3.9-10 mmol/L) from the start of exercise to the end of the study. RESULTS: The mean (95% confidence interval) times spent in hypoglycaemia (<3.9 mmol/L) after the start of exercise were 0.3% (-0.1, 0.7) for APX, 3.1% (0.8, 5.3) for APN, and 0.8% (0.1, 1.4) for SAP therapy. There was an absolute difference of 2.8% less time spent in hypoglycaemia for APX versus APN (p = .001) and 0.5% less time spent in hypoglycaemia for APX versus SAP therapy (p = .16). Mean time spent in euglycaemia was similar across the different sessions. CONCLUSIONS: Adjusting insulin and glucagon delivery at exercise onset within a dual-hormone AP significantly reduces hypoglycaemia compared with no adjustment and performs similarly to SAP therapy when insulin is adjusted before exercise.
RCT Entities:
AIMS: To test whether adjusting insulin and glucagon in response to exercise within a dual-hormone artificial pancreas (AP) reduces exercise-related hypoglycaemia. MATERIALS AND METHODS: In random order, 21 adults with type 1 diabetes (T1D) underwent three 22-hour experimental sessions: AP with exercise dosing adjustment (APX); AP with no exercise dosing adjustment (APN); and sensor-augmented pump (SAP) therapy. After an overnight stay and 2 hours after breakfast, participants exercised for 45 minutes at 60% of their maximum heart rate, with no snack given before exercise. During APX, insulin was decreased and glucagon was increased at exercise onset, while during SAP therapy, subjects could adjust dosing before exercise. The two primary outcomes were percentage of time spent in hypoglycaemia (<3.9 mmol/L) and percentage of time spent in euglycaemia (3.9-10 mmol/L) from the start of exercise to the end of the study. RESULTS: The mean (95% confidence interval) times spent in hypoglycaemia (<3.9 mmol/L) after the start of exercise were 0.3% (-0.1, 0.7) for APX, 3.1% (0.8, 5.3) for APN, and 0.8% (0.1, 1.4) for SAP therapy. There was an absolute difference of 2.8% less time spent in hypoglycaemia for APX versus APN (p = .001) and 0.5% less time spent in hypoglycaemia for APX versus SAP therapy (p = .16). Mean time spent in euglycaemia was similar across the different sessions. CONCLUSIONS: Adjusting insulin and glucagon delivery at exercise onset within a dual-hormone AP significantly reduces hypoglycaemia compared with no adjustment and performs similarly to SAP therapy when insulin is adjusted before exercise.
Authors: Sarah K McMahon; Luis D Ferreira; Nirubasini Ratnam; Raymond J Davey; Leanne M Youngs; Elizabeth A Davis; Paul A Fournier; Timothy W Jones Journal: J Clin Endocrinol Metab Date: 2006-11-21 Impact factor: 5.958
Authors: Eva Tsalikian; Craig Kollman; William B Tamborlane; Roy W Beck; Rosanna Fiallo-Scharer; Larry Fox; Kathleen F Janz; Katrina J Ruedy; Darrell Wilson; Dongyuan Xing; Stuart A Weinzimer Journal: Diabetes Care Date: 2006-10 Impact factor: 19.112
Authors: Steven J Russell; Firas H El-Khatib; Manasi Sinha; Kendra L Magyar; Katherine McKeon; Laura G Goergen; Courtney Balliro; Mallory A Hillard; David M Nathan; Edward R Damiano Journal: N Engl J Med Date: 2014-06-15 Impact factor: 91.245
Authors: Jane E Yardley; Glen P Kenny; Bruce A Perkins; Michael C Riddell; Nadia Balaa; Janine Malcolm; Pierre Boulay; Farah Khandwala; Ronald J Sigal Journal: Diabetes Care Date: 2012-11-19 Impact factor: 19.112
Authors: Jennifer L Sherr; Eda Cengiz; Cesar C Palerm; Bud Clark; Natalie Kurtz; Anirban Roy; Lori Carria; Martin Cantwell; William V Tamborlane; Stuart A Weinzimer Journal: Diabetes Care Date: 2013-06-11 Impact factor: 19.112
Authors: Gregory P Forlenza; Faye M Cameron; Trang T Ly; David Lam; Daniel P Howsmon; Nihat Baysal; Georgia Kulina; Laurel Messer; Paula Clinton; Camilla Levister; Stephen D Patek; Carol J Levy; R Paul Wadwa; David M Maahs; B Wayne Bequette; Bruce A Buckingham Journal: Diabetes Technol Ther Date: 2018-04-16 Impact factor: 6.118
Authors: Laya Ekhlaspour; Gregory P Forlenza; Daniel Chernavvsky; David M Maahs; R Paul Wadwa; Mark D Deboer; Laurel H Messer; Marissa Town; Jennifer Pinnata; Geoff Kruse; Boris P Kovatchev; Bruce A Buckingham; Marc D Breton Journal: Pediatr Diabetes Date: 2019-05-23 Impact factor: 4.866
Authors: Clara Mosquera-Lopez; Robert Dodier; Nichole S Tyler; Leah M Wilson; Joseph El Youssef; Jessica R Castle; Peter G Jacobs Journal: Diabetes Technol Ther Date: 2020-05-14 Impact factor: 6.118